All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
Powering insights from Cortellis. Link to Cortellis page on Clarivate website.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing the state of COVID-19 testing
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 20, 2021
Home
» XL-092: a promising pan-tyrosine kinase inhibitor in clinical development
XL-092: a promising pan-tyrosine kinase inhibitor in clinical development
Published at: Oct. 29, 2020
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=174587
BioWorld Science
Related Articles
Preclinical evaluation of SPR-519, a novel dual PI3K-alpha and mTOR kinase inhibitor